Outlook Therapeutics (NASDAQ:OTLK) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Outlook Therapeutics (NASDAQ:OTLK) in a research note published on Friday morning,Benzinga reports. HC Wainwright currently has a $30.00 price objective on the stock.

Other equities research analysts have also issued reports about the stock. BTIG Research restated a “buy” rating and issued a $50.00 price objective on shares of Outlook Therapeutics in a report on Friday, October 18th. Chardan Capital restated a “buy” rating and issued a $53.00 price target on shares of Outlook Therapeutics in a research note on Friday, August 16th. Finally, Ascendiant Capital Markets lowered their price objective on Outlook Therapeutics from $35.00 to $33.00 and set a “buy” rating for the company in a research report on Tuesday, September 3rd. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $42.34.

Outlook Therapeutics Stock Up 20.6 %

Shares of NASDAQ:OTLK opened at $2.05 on Friday. Outlook Therapeutics has a fifty-two week low of $0.87 and a fifty-two week high of $12.85. The firm’s 50 day moving average price is $5.29 and its 200 day moving average price is $6.70. The stock has a market cap of $48.50 million, a price-to-earnings ratio of -0.19 and a beta of 0.62.

Insider Buying and Selling at Outlook Therapeutics

In other news, CFO Lawrence A. Kenyon acquired 5,000 shares of the firm’s stock in a transaction dated Thursday, September 26th. The stock was acquired at an average cost of $5.69 per share, with a total value of $28,450.00. Following the completion of the acquisition, the chief financial officer now owns 5,946 shares of the company’s stock, valued at $33,832.74. The trade was a 528.54 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.40% of the stock is currently owned by insiders.

Institutional Trading of Outlook Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of OTLK. Great Point Partners LLC raised its holdings in Outlook Therapeutics by 15.0% during the second quarter. Great Point Partners LLC now owns 1,701,510 shares of the company’s stock worth $12,557,000 after purchasing an additional 221,510 shares in the last quarter. Rosalind Advisors Inc. increased its position in Outlook Therapeutics by 44.3% during the 2nd quarter. Rosalind Advisors Inc. now owns 450,000 shares of the company’s stock worth $3,321,000 after purchasing an additional 138,225 shares during the period. Geode Capital Management LLC raised its stake in shares of Outlook Therapeutics by 49.2% during the 3rd quarter. Geode Capital Management LLC now owns 341,959 shares of the company’s stock worth $1,826,000 after buying an additional 112,812 shares in the last quarter. LVW Advisors LLC acquired a new stake in shares of Outlook Therapeutics in the 2nd quarter valued at approximately $352,000. Finally, Susquehanna Fundamental Investments LLC purchased a new stake in shares of Outlook Therapeutics in the second quarter valued at approximately $303,000. Hedge funds and other institutional investors own 11.20% of the company’s stock.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.